Jennifer E Hardingham (J E Hardingham, Jennifer Hardingham)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2021
Publications (10 Years): 17

Top Venues

Pharmaceuticals (Basel, Switzerland)

Molecules (Basel, Switzerland)

International journal of molecular sciences

Journal of breast cancer

Queen Elizabeth Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Queen Elizabeth Hospital

Australia

Team Leader :: Oncology

Publications

Maryam Nakhjavani, Eric Smith, Kenny Yeo, Helen M Palethorpe, Yoko Tomita, Tim J Price, Amanda R Townsend, Jennifer E Hardingham
Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments. Cancers 13 (9) (2021)
Maryam Nakhjavani, Eric Smith, Helen M Palethorpe, Yoko Tomita, Kenny Yeo, Tim J Price, Amanda R Townsend, Jennifer E Hardingham
Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models. Pharmaceuticals (Basel, Switzerland) 14 (7) (2021)
Yoko Tomita, Eric Smith, Helen M Palethorpe, Maryam Nakhjavani, Kenny K L Yeo, Amanda R Townsend, Timothy J Price, Andrea J Yool, Jennifer E Hardingham
In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity. Pharmaceuticals (Basel, Switzerland) 14 (5) (2021)
Reger R Mikaeel, Joanne P Young, Gonzalo Tapia Rico, Peter J Hewett, Jennifer E Hardingham, Wendy Uylaki, Mehgan Horsnell, Timothy Jay Price
Immunohistochemistry features and molecular pathology of appendiceal neoplasms. Critical reviews in clinical laboratory sciences 58 (6) (2021)
Maryam Nakhjavani, Eric Smith, Amanda R Townsend, Timothy J Price, Jennifer E Hardingham
Anti-Angiogenic Properties of Ginsenoside Rg3. Molecules (Basel, Switzerland) 25 (21) (2020)
Chandra Kirana, Eric Smith, Doan T Ngo, Markus I Trochsler, Peter J Hewett, Richard S Stubbs, Jennifer E Hardingham, Guy J Maddern, Ehud Hauben
High preoperative levels of circulating SFRP5 predict better prognosis in colorectal cancer patients. Future oncology (London, England) 16 (31) (2020)
Reger R Mikaeel, Joanne P Young, Jennifer E Hardingham, Gonzalo Tapia Rico, Peter J Hewett, Erin Leigh Symonds, Suzanne Melissa Edwards, Eric Smith, Yoko Tomita, Wendy Uylaki, Mehgan Horsnell, Timothy Jay Price
Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. Expert review of gastroenterology & hepatology 15 (2) (2020)
Helen M Palethorpe, Eric Smith, Yoko Tomita, Maryam Nakhjavani, Andrea J Yool, Timothy J Price, Joanne P Young, Amanda R Townsend, Jennifer E Hardingham
Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. Molecules (Basel, Switzerland) 24 (19) (2019)
Yoko Tomita, Helen M Palethorpe, Eric Smith, Maryam Nakhjavani, Amanda R Townsend, Timothy J Price, Andrea J Yool, Jennifer E Hardingham
Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro. International journal of molecular sciences 20 (8) (2019)
Eric Smith, Yoko Tomita, Helen M Palethorpe, Stuart Howell, Maryam Nakhjavani, Amanda R Townsend, Timothy Jay Price, Joanne P Young, Jennifer E Hardingham
Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. Epigenetics 14 (2) (2019)
Maryam Nakhjavani, Jennifer E Hardingham, Helen M Palethorpe, Yoko Tomita, Eric Smith, Tim J Price, Amanda R Townsend
Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer. Medicines (Basel, Switzerland) 6 (1) (2019)
Maryam Nakhjavani, Jennifer E Hardingham, Helen M Palethorpe, Timothy Jay Price, Amanda R Townsend
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. Journal of breast cancer 22 (3) (2019)
Michael L De Ieso, Jinxin V Pei, Saeed Nourmohammadi, Eric Smith, Pak Hin Chow, Mohamad Kourghi, Jennifer E Hardingham, Andrea J Yool
Combined pharmacological administration of AQP1 ion channel blocker AqB011 and water channel blocker Bacopaside II amplifies inhibition of colon cancer cell migration. Scientific reports 9 (1) (2019)
Amanda Townsend, Niall Tebbutt, Christos Karapetis, Pamela Cooper, Nimit Singhal, Susan Yeend, Louise Pirc, Rohit Joshi, Jennifer E Hardingham, Timothy Price
Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (16) (2018)
Helen M Palethorpe, Yoko Tomita, Eric Smith, Jinxin V Pei, Amanda R Townsend, Timothy J Price, Joanne P Young, Andrea J Yool, Jennifer E Hardingham
The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. International journal of molecular sciences 19 (3) (2018)
Eric Smith, Helen M Palethorpe, Yoko Tomita, Jinxin V Pei, Amanda R Townsend, Timothy J Price, Joanne P Young, Andrea J Yool, Jennifer E Hardingham
The Purified Extract from the Medicinal Plant Bacopa monnieri, Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. Cells 7 (7) (2018)
S S Kumar, Y Tomita, J Wrin, M Bruhn, A Swalling, M Mohammed, T J Price, Jennifer E Hardingham
High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 19 (6) (2016)

Jennifer E Hardingham.css-eqlu8i{font-size:small;padding-left:4px;} (J E Hardingham, Jennifer Hardingham)

Publication Activity (10 Years)

Top Topics

Top Venues

Jennifer E Hardingham (J E Hardingham, Jennifer Hardingham)